The hypoxia imaging agent Cu-II(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease
AuthorHung, LW; Villemagne, VL; Cheng, L; Sherratt, NA; Ayton, S; White, AR; Crouch, PJ; Lim, S; Leong, SL; Wilkins, S; ...
Source TitleJOURNAL OF EXPERIMENTAL MEDICINE
PublisherROCKEFELLER UNIV PRESS
University of Melbourne Author/sVillemagne, Victor; Cheng, Lesley; SHERRATT, NICKI; Masters, Colin; Crouch, Peter; Donnelly, Paul; Cappai, Roberto; PHAM, CHI; Culvenor, Janetta; Hill, Andrew; ...
AffiliationFlorey Department of Neuroscience and Mental Health
Medicine, Dentistry & Health Sciences
Medicine and Radiology
Biochemistry and Molecular Biology
Pharmacology and Therapeutics
School of Chemistry
Document TypeJournal Article
CitationsHung, L. W., Villemagne, V. L., Cheng, L., Sherratt, N. A., Ayton, S., White, A. R., Crouch, P. J., Lim, S., Leong, S. L., Wilkins, S., George, J., Roberts, B. R., Pham, C. L. L., Liu, X., Chiu, F. C. K., Shackleford, D. M., Powell, A. K., Masters, C. L., Bush, A. I. ,... Barnham, K. J. (2012). The hypoxia imaging agent Cu-II(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. JOURNAL OF EXPERIMENTAL MEDICINE, 209 (4), pp.837-854. https://doi.org/10.1084/jem.20112285.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328361
NHMRC Grant codeNHMRC/1037234
Parkinson's disease (PD) is a progressive, chronic disease characterized by dyskinesia, rigidity, instability, and tremors. The disease is defined by the presence of Lewy bodies, which primarily consist of aggregated α-synuclein protein, and is accompanied by the loss of monoaminergic neurons. Current therapeutic strategies only give symptomatic relief of motor impairment and do not address the underlying neurodegeneration. Hence, we have identified Cu(II)(atsm) as a potential therapeutic for PD. Drug administration to four different animal models of PD resulted in improved motor and cognition function, rescued nigral cell loss, and improved dopamine metabolism. In vitro, this compound is able to inhibit the effects of peroxynitrite-driven toxicity, including the formation of nitrated α-synuclein oligomers. Our results show that Cu(II)(atsm) is effective in reversing parkinsonian defects in animal models and has the potential to be a successful treatment of PD.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References
- University General - Research Publications 
- School of Chemistry - Research Publications 
- Pharmacology and Therapeutics - Research Publications 
- Pathology - Research Publications 
- Biochemistry and Molecular Biology - Research Publications 
- Medicine and Radiology - Research Publications 
- Clinical Pathology - Research Publications 
- Medicine, Dentistry & Health Sciences Collected Works - Research Publications 
- Florey Department of Neuroscience and Mental Health - Research Publications